Remove Clinical Development Remove Pharma Companies Remove Regulations
article thumbnail

Metabolite Bioanalysis

Metabolite Tales Blog

Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group A Metabolite Bioanalysis Working Group comprised of experts from 14 different pharma companies have proposed recommendations around best practice in metabolite bioanalysis during drug development.

article thumbnail

BioSpace Movers & Shakers, Dec. 18

The Pharma Data

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. Immune Regulation – U.K.-based

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What type of R&D efforts are needed to develop value added medicines?

Altus Drug Development

What R&D efforts are needed to develop value-added medicines? A considerable R&D investment is required to optimize health systems and develop new drugs and therapeutic devices. A clinical development program may be required for the proper health technology assessment of value-added medicines.

article thumbnail

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

The Pharma Data

The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect,” says Anna Ljung, CEO of Moberg Pharma. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 CET on November 6, 2020.

article thumbnail

AstraZeneca Closes in on Potential UK Vaccine Authorization and Other COVID-19 News

The Pharma Data

Recombinant monoclonal antibodies are designed to enhance the immune system’s ability to regulate cell functions. The company currently plans to include more than 4,000 participants in additional trials, which it believes could support an initial regulatory approval as soon as the fourth quarter of 2021. government in September.

Vaccine 52